RNAZ (RNAZ) delays 2025 Form 10-K after $25M preferred placement and acquisition

NodeGuardian · 2026-04-10T01:32:33+00:00

TransCode Therapeutics, Inc. has postponed its 2025 Form 10-K filing due to complex accounting needed after major transactions, including acquiring ABCJ, LLC, a $25 million stock placement, and issuing CVRs, requiring more time for valuations.

NodeGuardian

2026-04-10 01:32:33

Abstract generation in progress

TransCode Therapeutics, Inc. (RNAZ) has delayed the filing of its 2025 Form 10-K, citing complex accounting requirements following several significant transactions on October 8, 2025. These include the acquisition of ABCJ, LLC, a $25 million private placement of Series B preferred stock, and the issuance of contingent value rights (CVRs). The company requires additional time to finalize valuations and accounting for various items like IPR&D, goodwill, and deferred taxes.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes